Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) EBT Margin (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBT Margin for 8 consecutive years, with 37.81% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 375944.0% to 37.81% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 143.97% through Dec 2025, down 11314.0% year-over-year, with the annual reading at 143.97% for FY2025, 11314.0% down from the prior year.
  • EBT Margin for Q4 2025 was 37.81% at Precision Biosciences, up from 153861.54% in the prior quarter.
  • The five-year high for EBT Margin was 50.96% in Q2 2024, with the low at 153861.54% in Q3 2025.
  • Average EBT Margin over 5 years is 17704.94%, with a median of 161.84% recorded in 2022.
  • Peak annual rise in EBT Margin hit 375944bps in 2025, while the deepest fall reached -15042959bps in 2025.
  • Over 5 years, EBT Margin stood at 484.52% in 2021, then soared by 79bps to 100.57% in 2022, then tumbled by -93bps to 193.83% in 2023, then plummeted by -1820bps to 3721.63% in 2024, then soared by 101bps to 37.81% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 37.81%, 153861.54%, and 117327.78% for Q4 2025, Q3 2025, and Q2 2025 respectively.